Ernst R Berndt

Summary

Affiliation: Massachusetts Institute of Technology
Country: USA

Publications

  1. ncbi Authorized generic drugs, price competition, and consumers' welfare
    Ernst R Berndt
    Sloan School of Management, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA
    Health Aff (Millwood) 26:790-9. 2007
  2. ncbi Industry funding of the FDA: effects of PDUFA on approval times and withdrawal rates
    Ernst R Berndt
    Sloan School of Management, Massachusetts Institute of Technology, 50 Memorial Drive, E52 452, Cambridge, MA 02142, USA
    Nat Rev Drug Discov 4:545-54. 2005
  3. ncbi Advance market commitments for vaccines against neglected diseases: estimating costs and effectiveness
    Ernst R Berndt
    MIT Sloan School of Management, USA
    Health Econ 16:491-511. 2007
  4. ncbi Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers
    Mark R Trusheim
    MIT Center for Biomedical Innovation, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139 4307, USA
    Nat Rev Drug Discov 6:287-93. 2007
  5. ncbi Pharmaceuticals in U.S. health care: determinants of quantity and price
    Ernst R Berndt
    MIT Sloan School of Management, Cambridge, Massachusetts, USA
    J Econ Perspect 16:45-66. 2002
  6. ncbi Changes in the costs of treating mental health disorders: an overview of recent research findings
    Ernst R Berndt
    Alfred P Sloan School of Management, Massachusetts Institute of Technology, and the National Bureau of Economic Research, Cambridge, MA 02142, USA
    Pharmacoeconomics 22:37-50. 2004
  7. ncbi To inform or persuade? Direct-to-consumer advertising of prescription drugs
    Ernst R Berndt
    Massachusetts Institute of Technology, Cambridge, USA
    N Engl J Med 352:325-8. 2005
  8. ncbi The value of antihypertensive drugs: a perspective on medical innovation
    David M Cutler
    Department of Economics, Harvard University, Cambridge, Massachusetts, USA
    Health Aff (Millwood) 26:97-110. 2007
  9. ncbi Vaccine advance-purchase agreements for low-income countries: practical issues
    Ernst R Berndt
    Sloan School of Management, Massachusetts Institute of Technology, Cambridge, MA, USA
    Health Aff (Millwood) 24:653-65. 2005
  10. ncbi An analysis of the diffusion of new antidepressants: variety, quality, and marketing efforts
    Ernst R Berndt
    Massachusetts Institute of Technology, Cambridge, MA 02142, USA
    J Ment Health Policy Econ 5:3-19. 2002

Detail Information

Publications20

  1. ncbi Authorized generic drugs, price competition, and consumers' welfare
    Ernst R Berndt
    Sloan School of Management, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA
    Health Aff (Millwood) 26:790-9. 2007
    ..We posit that long-run prices and shares are likely essentially unaffected by authorized generics and that potential costs to consumers from any delayed generic entry are likely small...
  2. ncbi Industry funding of the FDA: effects of PDUFA on approval times and withdrawal rates
    Ernst R Berndt
    Sloan School of Management, Massachusetts Institute of Technology, 50 Memorial Drive, E52 452, Cambridge, MA 02142, USA
    Nat Rev Drug Discov 4:545-54. 2005
    ....
  3. ncbi Advance market commitments for vaccines against neglected diseases: estimating costs and effectiveness
    Ernst R Berndt
    MIT Sloan School of Management, USA
    Health Econ 16:491-511. 2007
    ..Readers can conduct their own sensitivity analyses employing a web-based spreadsheet tool...
  4. ncbi Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers
    Mark R Trusheim
    MIT Center for Biomedical Innovation, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139 4307, USA
    Nat Rev Drug Discov 6:287-93. 2007
    ....
  5. ncbi Pharmaceuticals in U.S. health care: determinants of quantity and price
    Ernst R Berndt
    MIT Sloan School of Management, Cambridge, Massachusetts, USA
    J Econ Perspect 16:45-66. 2002
  6. ncbi Changes in the costs of treating mental health disorders: an overview of recent research findings
    Ernst R Berndt
    Alfred P Sloan School of Management, Massachusetts Institute of Technology, and the National Bureau of Economic Research, Cambridge, MA 02142, USA
    Pharmacoeconomics 22:37-50. 2004
    ..However, a substantial portion of treatment is not supported by clinical evidence...
  7. ncbi To inform or persuade? Direct-to-consumer advertising of prescription drugs
    Ernst R Berndt
    Massachusetts Institute of Technology, Cambridge, USA
    N Engl J Med 352:325-8. 2005
  8. ncbi The value of antihypertensive drugs: a perspective on medical innovation
    David M Cutler
    Department of Economics, Harvard University, Cambridge, Massachusetts, USA
    Health Aff (Millwood) 26:97-110. 2007
    ..More effective use of antihypertensive medication would have an impact on mortality akin to eliminating all deaths from medical errors or accidents...
  9. ncbi Vaccine advance-purchase agreements for low-income countries: practical issues
    Ernst R Berndt
    Sloan School of Management, Massachusetts Institute of Technology, Cambridge, MA, USA
    Health Aff (Millwood) 24:653-65. 2005
    ..We identify several practical issues that we believe the public health and policy community should consider further in the design of an advance-purchase commitment...
  10. ncbi An analysis of the diffusion of new antidepressants: variety, quality, and marketing efforts
    Ernst R Berndt
    Massachusetts Institute of Technology, Cambridge, MA 02142, USA
    J Ment Health Policy Econ 5:3-19. 2002
    ..The overall level and market share success of the various selective serotonin reuptake inhibitors ( SSRIs ) relative to a representative older generation tricyclic (such as amitriptyline) provides a useful focus for studying such issues...
  11. ncbi The impact of treatment-resistant depression on health care utilization and costs
    William H Crown
    MEDSTAT Group, Cambridge, Mass, USA
    J Clin Psychiatry 63:963-71. 2002
    ..These findings underscore the need for early identification and effective long-term maintenance treatment for treatment-resistant depression...
  12. ncbi Promotion of prescription drugs to consumers
    Meredith B Rosenthal
    Department of Health Policy and Management, Harvard School of Public Health, Boston, MA 02115, USA
    N Engl J Med 346:498-505. 2002
    ..Guidelines issued in 1997 by the Food and Drug Administration (FDA) regarding advertising to consumers through electronic media are considered by some to be responsible for unleashing a flood of direct-to-consumer advertising...
  13. ncbi Effects of pharmaceutical promotion on adherence to the treatment guidelines for depression
    Julie M Donohue
    Department of Health Policy and Management, University of Pittsburgh, Pennsylvania 15261, USA
    Med Care 42:1176-85. 2004
    ....
  14. ncbi Treatment costs of venlafaxine and selective serotonin-reuptake inhibitors for depression and anxiety
    George J Wan
    Wyeth Research, Philadelphia, USA
    Manag Care Interface 15:24-30. 2002
    ..472, respectively; P = .02), but total health care expenditures were not significantly different...
  15. ncbi Generic entry, reformulations and promotion of SSRIs in the US
    Haiden A Huskamp
    Department of Health Care Policy, Harvard Medical School, Boston, MA 02115, USA
    Pharmacoeconomics 26:603-16. 2008
    ..However, little is known about how newer strategies to extend patent life, including product reformulation introduction or obtaining approval to market for additional clinical indications, influence promotion...
  16. ncbi Being direct
    Julie M Donohue
    Department of Health Policy and Management, University of Pittsburgh, Graduate School of Public Health, USA
    Mark Health Serv 25:30-6. 2005
  17. ncbi Benefit plan design and prescription drug utilization among asthmatics: do patient copayments matter?
    William H Crown
    Front Health Policy Res 7:95-127. 2004
    ..There is no strong statistical evidence that higher levels of out-of-pocket copayments for prescription drugs influence asthma treatment patterns. However, physician/practice prescribing preferences influence patient treatment...
  18. ncbi Prescriber intent, off-label usage, and early discontinuation of antidepressants: a retrospective physician survey and data analysis
    Jay M Pomerantz
    Health New England, Springfield, MA, USA
    J Clin Psychiatry 65:395-404. 2004
    ..We explore various possibilities, including prescriber intent and patient diagnosis, to explain some of this early discontinuation...
  19. ncbi Depression treatment: a lifelong commitment?
    Martin B Keller
    Department of Psychiatry and Human Behavior, Brown University, Providence, RI 02906, USA
    Psychopharmacol Bull 36:133-41. 2002
    ..Additional well-designed studies addressing these issues are urgently needed...
  20. ncbi The medical treatment of depression, 1991-1996: productive inefficiency, expected outcome variations, and price indexes
    Ernst R Berndt
    MIT and NBER, Boston, MA 02127, USA
    J Health Econ 21:373-96. 2002
    ..Based on hedonic regression equations that account for the effects of changing patient mix, we find reductions that range from about -1.66 to -2.13% per year...